Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.
    Benzinga,  Biotechnology,  Health,  Nature,  Regenerative Medicine

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022 /

    Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market  is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …

    read more
    Jessica N. Abraham Comments Off on Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    You May Also Like

    Generation Hemp is a pure-play leader in the industrial hemp industry.

    Generation Hemp Reports Quarterly Financial Statements to SEC, Announces New Processing Contracts and Brand Launches

    August 21, 2021
    parcelpost parcelpal Last week, ParcelPal Logistics Inc. (OTCQB: PTNYF), a US and Canadian-based organization specializing in last-mile delivery services and logistics-related solutions, announced that it would acquire another well-known and currently unnamed U.S. delivery service, citing a “letter of intent” between both parties after almost 8 months of successful, rapidly-growing co-operations at the company’s west coast facility.

    US and Canadian Delivery Service to Acquire Another U.S. Delivery Services Company, Executes New Canadian Service Agreement in the Same Week

    December 2, 2021
    Renewable Energy, Solar Panels, Clean Energy 2030, Benzinga, SinglePoint, Jessica Abraham

    An Empire For Solar Discovery And Education In The Making? SinglePoint Reports Building Out Network For Clean Air And Green Energy Efficiency

    March 17, 2022
  • Cell Transplant, Eye Transplant, Cellular Regeneration, Regeneration Therapy,
    Health,  Benzinga,  Biotechnology,  Business,  Finance,  Regenerative Medicine

    Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy

    October 21, 2021 /

    Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA).  Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease.  The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…

    read more
    Jessica N. Abraham Comments Off on Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy

    You May Also Like

    Green Policy, Generation Hemp, Melissa Pagen, Gary C Evans, Industrial Hemp Processor, Hemp Cleaning, Green Policy, ESG

    Generation Hemp’s Green Policy is Inspired by a Cause, Executives Move From Oil and Gas to Industrial Green

    August 30, 2021
    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
    Generation Hemp is a Pure-Play industrial hemp company that focuses on providing sustainability within the industrial hemp sector.

    Is Generation Hemp Now A Leader in Pure-Play Hemp Operations for the Industrial Sector?

    October 28, 2021
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.